Antithrombotic Use with Collagenase Clostridium Histolyticum Injection to Treat Dupuytren Disease

J Hand Surg Asian Pac Vol. 2021 Dec;26(4):599-610. doi: 10.1142/S2424835521500570.

Abstract

Background: Collagenase Clostridium histolyticum (collagenase) is an injectable treatment option for Dupuytren disease. The current study was designed to investigate the safety and ensure the effectiveness of collagenase for the treatment of Dupuytren disease, with or without concomitant antithrombotic usage. Methods: One hundred and forty-eight patients with Dupuytren disease were treated with collagenase during this period; 49 taking antithrombotics and 99 not taking antithrombotics. The primary outcomes were clinical success (a reduction in joint contracture to < 5°) and clinical improvement (a reduction in joint contracture by equal to or more than 50%). Results: No statistically significant difference in either clinical success or clinical improvement was found between those taking and those not taking antithrombotics. No significant difference was found in the incidence of any adverse effects or skin splits between the two cohorts. Conclusions: Collagenase can be safely and effectively used to treat patients with Dupuytren disease who take antithrombotics.

Keywords: Antithrombotics; Clinical success; Collagenase; Dupuytren.

MeSH terms

  • Collagenases
  • Dupuytren Contracture* / drug therapy
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Microbial Collagenase*
  • Treatment Outcome

Substances

  • Fibrinolytic Agents
  • Collagenases
  • Microbial Collagenase